ANI Pharmaceuticals announced it will appeal to the Delaware Supreme Court after a trial court denied its motions for a new trial and judgment as a matter of law in its dispute with CG Oncology. The company is seeking to recover the value of assets it sold to CG Oncology under a 2010 agreement, including a 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec. Judge Sheldon K. Rennie issued the denial on July 16, 2026. President and CEO Nikhil Lalwani stated the company respectfully disagrees with the decision and intends to vigorously pursue its legal rights.
ANI Pharmaceuticals IncCourt denied new trial, ANI to appeal; legal setback threatens royalty revenue from CG Oncology.